Thematics Asset Management Purchases 216,937 Shares of CryoPort, Inc. $CYRX

Thematics Asset Management grew its position in shares of CryoPort, Inc. (NASDAQ:CYRX) by 12.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,914,885 shares of the company’s stock after purchasing an additional 216,937 shares during the period. Thematics Asset Management owned about 3.82% of CryoPort worth $14,285,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Federated Hermes Inc. bought a new position in CryoPort during the first quarter valued at approximately $155,000. Charles Schwab Investment Management Inc. raised its position in CryoPort by 1.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 370,302 shares of the company’s stock worth $2,251,000 after purchasing an additional 5,207 shares during the period. Sierra Summit Advisors LLC lifted its stake in CryoPort by 5.0% in the first quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company’s stock worth $274,000 after purchasing an additional 2,150 shares during the last quarter. Invesco Ltd. boosted its position in CryoPort by 18.1% during the first quarter. Invesco Ltd. now owns 61,190 shares of the company’s stock valued at $372,000 after buying an additional 9,387 shares during the period. Finally, Nuveen LLC bought a new position in shares of CryoPort during the first quarter valued at about $743,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CYRX has been the topic of several recent research reports. UBS Group raised their price target on CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. BTIG Research raised their target price on shares of CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of CryoPort in a report on Monday, November 24th. Finally, Needham & Company LLC increased their price target on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CryoPort has a consensus rating of “Moderate Buy” and a consensus target price of $12.83.

CryoPort Trading Down 3.4%

Shares of CYRX opened at $9.54 on Monday. CryoPort, Inc. has a 1-year low of $4.58 and a 1-year high of $11.44. The company has a current ratio of 15.77, a quick ratio of 15.01 and a debt-to-equity ratio of 0.40. The firm’s 50-day moving average price is $9.40 and its 200-day moving average price is $8.39. The firm has a market capitalization of $477.67 million, a price-to-earnings ratio of 8.15 and a beta of 1.51.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. The business had revenue of $44.23 million during the quarter, compared to analyst estimates of $41.22 million. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. Sell-side analysts anticipate that CryoPort, Inc. will post -0.99 EPS for the current year.

Insider Buying and Selling at CryoPort

In related news, Director Robert J. Hariri sold 25,000 shares of the company’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $9.71, for a total value of $242,750.00. Following the sale, the director directly owned 51,275 shares of the company’s stock, valued at $497,880.25. This represents a 32.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.10% of the stock is owned by corporate insiders.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.